LLY · NYSE
Eli Lilly and Company
$1,274.96 -33.40 (-2.55%)
Company overview
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio for HR…
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Exchange
- NYSE
- Market cap
- $1.2T
- Employees
- 47,000
- Headquarters
- Indianapolis, IN
- Website
- lilly.com
- CEO
- David A. Ricks
- Listed
- June 1, 1972
- P/E
- 45.21
- Dividend yield
- 0.57%
Company financials
- Revenue
- $72.2B
- Gross profit
- $60.3B
- Operating income
- $33.1B
- EBITDA
- $33.1B
- Net income
- $25.3B
- EPS
- $28.20
- Total assets
- $117B
- Total debt
- $43.4B
- Gross margin
- 83.51%
- Net margin
- 34.98%
- Earnings yield
- 2.21%
Showing FY 2025
LLY
1D
NYSE
O1,281.76H1,321.21L1,275.10C1,306.69+35.94 (+2.83%)Vol2.66M